[STUDY_ID_REMOVED]  
 
Study ID : RAP -MD-06 
 
 
 
Title:  An Open -label, Long -term Safety Study of Rapastinel as Adjunctive Therapy in Patients With 
Major Depressive Disorder 
 
 
Protocol  Date : 07 Jun  2016  
 
1.0 TITLE PAGE
Naurex, Inc, an affiliate of Allergan, plc.
Harborside Financial Center, Plaza V
Jersey City, NJ 07311
An Open -label , Long-term Safety S tudy of Rapastinel as Adjunctive Therapy in
Patients with M ajor Depressive D isorder
RAP -MD-06
IND # 107,974
Original Protocol Date: 07 Jun 2016
Confidentiality Statement
This document is the property of Allergan, plc and may not —in full or part— be passed 
on, reproduced, published, distributed, or submitted to any regulatory authority without 
the express written permission of Allergan, plc . 
RAP-MD-06 Protocol Page 1 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
2.0 SYNOPSIS AND SCHEDULE OF EVALUATIONS
CLINICAL STUDY SYNOPSIS: Study RAP -MD-06
Title of StudyAn Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in 
Patientswith Major Depressive Disorder
Study Centers (Country) Approximately 105 to110 study centers (United States)
Development Phase 3
ObjectiveTo evaluate the long -term safety and tolerability of rapastinel as an adjunctive to 
antidepressant therapy (ADT) in patients with major depressive disorder (MDD )
MethodologyMulticenter, open -label, long -term study in adult patients with a primary 
diagnosis of MDD.
For patients enrolling from RAP -MD-04,the final vis it from that study (ie, 
Visit122)will serve as Visit 1 in RAP -MD-06 and,after obtaining informed 
consent, open-label rapastinel will be administered at Visit 1 to ensure 
continuity of treatment. 
The enrollment of patients who did not participate in RAP-MD -04 (identified as 
de novoenrollment patients) may be allowed at select study centers at the 
discretion of the Sponsor in the event that overall program enrollment indicates 
such de novoenrollment is necessary.  Should de novopatients be enrolled with 
Sponsor approval, such patients will include adult patients with MDD who have 
no more than a partial response (defined as < 50% improvement) to ongoing 
ADT treatment in the current episode. Upon written informed consent, de novo
enrollment patients will enter a screening period of up to 14 days.  
Following the screening period, all patients will enter the 52 -week Open-label
Treatment Period (OLTP).  The OLTPconsists of weekly or biweekly ( once 
every 2 weeks, based on Investigato r discretion) visits for up to52 weeks. 
Upon completion of the OLTP, patients will enter a 2-week safety follow-up 
period.
Number of PatientsApproximately 500 patients are expected to enter the OLTP.The study will be 
terminated when 100 patients have completed the 52-week OLTP.
Diagnosis and Main Criteria for InclusionThe following are requirements for entry into the study (patients entering from 
RAP-MD-04 are considered to have met inclusion criteria for diagnosis, 
severity, and prior ADT response, and are not required to meet these criteria 
upon entry into RAP-MD-06):
Male orfemale outpatients ,ages 18 to 65 years who meet Diagnostic and 
Statistical Manual of Mental Disorders , Fifth Edition (DSM -5) criteria for 
MDD based on Structured Clinical Interview for Diagnostic Statistic Manual of Mental Health Disorders, Fifth Edition (SCID), with a current 
major depressive episode of at least 8 weeks and not exceeding 18 months 
in duration at Visit 1
Have no more  than partial response (< 50% improvement) to ongoing 
treatment with a protocol-allowed ADT (  
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 2 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

Test Product, Dosage ,and Mode of 
AdministrationRapastinel 450 mg given intravenously (IV) either weekly or biweekly, per 
Investigator discretion, as adjunctive to ongoing ADT during the OLTP.
Duration of TreatmentFor patients en rolling into RAP -MD-06 from RAP -MD-04 there will be a 
1-week screening period, up to 52 weeks of open -label rapastinel as adjunctive 
treatment to ongoing ADT, and a 2-week safety follow -up period. 
Should de novopatientsbe enrolled at a later date, there will be a screening 
period of up to 2 weeks ,up to52 weeks of open -label rapastinel as adjunctive 
treatment to ongoing ADT , anda 2-week safety follow -up period.
Reference Therapy, Dos age, and 
Mode of Adm inistrationNone
Criteria for Evaluation
Safety MeasuresAdverse event (AE) recording, clinical laboratory measures, vital sign 
parameters, electrocardiograms (ECGs), and physical examinations
Measure of psychotomimetic effects:Brief Psychiatric Rating Scale 
Positive Symptoms subscale (BPRS+)
Measure of dissociative effects: Clinician Administered D issociative States 
Scale (CADSS)
Phar macokinetic Analysis None
Phar macogenetic Analysis None
Statistical MethodsDescriptive statistics will be presented for all efficacy and safety parameters. No 
inferential statistical analyses will be performed.
All safety parameters will be summarized for the Safety Population, defined as 
all patients who receive at least 1 dose of investigational product (IP )in this 
study.
 
  
RAP-MD-06 Protocol Page 3 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 4 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 5 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
  
RAP-MD-06 Protocol Page 6 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

3.0 OVERALL TABLE OF CONTENTS 
 
 Page
1.0 TITLE PAGE ............................................................................................. . 
2.0 SYNOPSIS AND SCHEDULE OF EVALUATIONS .............................. . 
3.0 OVERALL TABLE OF CONTENTS ....................................................... . 
3.1 LIST OF IN-TEXT FIGURES................................................................ . 
4.0 LIST OF ABBREVIATIONS .................................................................... . 
5.0 ETHICAL CONSIDERATIONS ............................................................... . 
5.1 INSTITUTIONAL REVIEW BOARD .................................................. . 
5.2 ETHICAL CONDUCT OF THE STUDY .............................................. . 
5.3 PATIENT INFORMATION AND INFORMED CONSENT ................ . 
6.0 INVESTIGATORS AND STUDY ADMINISTRATIVE 
STRUCTURE .................................................................................................. . 
7.0 INTRODUCTION ..................................................................................... . 
8.0 STUDY OBJECTIVES .............................................................................. . 
9.0 INVESTIGATIONAL PLAN .................................................................... . 
9.1 OVERALL STUDY DESIGN A ND PLAN: DESCRIPTION .............. . 
9.1.1 Screening .......................................................................................... . 
9.1.2 Open-label Treatment Period ........................................................... . 
9.1.3 Safety Follow-up Period................................................................... . 
9.2 DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS ............................................................................
. 
9.3 SELECTION OF STUDY POPULATION ............................................ . 1
2
7
141517
17
1717
18
19
23242425
26
26
26
27 
RAP-MD-06 Protocol Page 7 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.3.1 Inclusion Criteria .............................................................................. . 
9.3.2 Exclusion Criteria ............................................................................. . 
9.3.3 Removal of Patients from Therapy or Assessment .......................... . 
9.3.4 Patient Replacement Procedures ...................................................... . 
9.4 TREATMENTS ...................................................................................... . 
9.4.1 Background Antidepressant Therapy ............................................... . 
9.4.2 Treatments Administered ................................................................. . 
9.4.3 Identity of Investigational Product ................................................... . 
9.4.4 Handling of Investigational Product ................................................ . 
9.4.5 Method of Assigning Patients to Treatment Groups ........................ . 
9.4.6 Selection of Dosages in the Study .................................................... . 
9.4.7 Selection and Timing of Dose for Each Patient ............................... . 
9.4.7.1 Screening Period ........................................................................ . 
9.4.7.2 Open-label Treatment Period ..................................................... . 
9.4.7.3 Safety Follow-up Period ............................................................ . 
9.4.8 Blinding ............................................................................................ . 
9.4.9 Unblinding ........................................................................................ . 
9.4.10 Prior and Concomitant Therapy ..................................................... . 
  
9.4.11 Other Restrictions ...........................................................................
. 
9.4.11.1 Alcohol ..................................................................................... . 
9.4.11.2 Contraception ........................................................................... . 27
2831
32
33333434
34
35353636
36
36363737
37
38383838 
RAP-MD-06 Protocol Page 8 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.4.12 Monitoring Treatment Compliance ................................................ . 
9.4.13 Treatment After Discontinuation ................................................... . 
9.5 EFFICACY AND SA FETY VARIABLES ............................................ . 
9.5.1 Diagnostic and Efficacy Assessments .............................................. . 
9.5.1.1 Diagnostic Assessments ............................................................. . 
  
. 
9.5.2 Safety Assessments .......................................................................... . 
9.5.2.1 Adverse Events .......................................................................... . 
9.5.2.1.1 Causality Assessment .......................................................... . 
9.5.2.1.2 Severity Assessment ............................................................ . 
9.5.2.1.3 Serious Adverse Events ....................................................... . 
9.5.2.1.4 Reporting Adverse Events  and Serious Adverse Events ..... . 
9.5.2.2 Immediate Reporting of Seri ous Adverse Events and Events 
of Special Interest .................................................................................. . 
9.5.2.3 Reporting of Pregnancies Occurring During the Study ............. . 
9.5.2.4 Potential Hy’s Law Cases .......................................................... . 
9.5.2.5 Clinical Laboratory Determinations .......................................... . 
9.5.2.6 Vital Signs .................................................................................. . 
9.5.2.7 Electrocardiograms .................................................................... .   39
3939
39
39404040
40
40414242
43
44
45
45
46
47484848 
RAP-MD-06 Protocol Page 9 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
9.5.2.8.3 Brief Psychiatric Rating Scale - Positive Symptoms 
Subscale .............................................................................................. . 
9.5.2.8.4 Clinician Administered  Dissociative States Scale ............... . 
     
 
    
 
 
 
 
 
 
 
 
    
9.5.6.9 Unscheduled Visits ....................................................................
. 
9.6 DATA QUALITY ASSURANCE.......................................................... . 49
49
50
50505051
51
51
51
51
53
54
54
55
56
57
58
5858 
RAP-MD-06 Protocol Page 10 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.6.1 Data Monitoring ............................................................................... . 
9.6.2 Data Recording and Documentation ................................................ . 
9.7 STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE ............................................................................................. . 
9.7.1 Analysis Populations ........................................................................ . 
9.7.1.1 Screened Population ................................................................... . 
9.7.1.2 Safety Population ....................................................................... . 
9.7.1.3 Intent-to-Treat Population .......................................................... . 
9.7.2 Patient Disposition ........................................................................... . 
9.7.3 Demographics and Other Baseline Characteristics .......................... . 
9.7.4 Extent of Exposure and Treatment Compliance .............................. . 
9.7.4.1 Extent of Exposure ..................................................................... . 
9.7.4.2 Measurement of Treatment Compliance .................................... . 
 
9.7.6 Safety Analyses ................................................................................ . 
9.7.6.1 Adverse Events .......................................................................... . 
9.7.6.2 Clinical Laboratory Parameters ................................................. . 
9.7.6.3 Vital Signs .................................................................................. . 
9.7.6.4 Electrocardiogram ...................................................................... . 
9.7.6.5 Other Safety Parameters ............................................................ .  
9.7.8 Interim Analysis ...............................................................................
. 
9.7.9 Determination of Sample Size .......................................................... . 58
59
60
60
606060
60
61616161
62
62636465
65
66666767 
RAP-MD-06 Protocol Page 11 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.7.10 Computer Methods ......................................................................... . 
9.8 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED 
ANALYSES ................................................................................................. . 
9.9 PROTOCOL DEVIATIONS .................................................................. . 
10.0 STUDY SPONSORSHIP......................................................................... . 
10.1 STUDY TERMINATION .................................................................... . 
10.2 REPORTING AND PUBLICATION .................................................. . 
11.0 INVESTIGATOR OBLIGATIONS ........................................................ . 
11.1 DOCUMENTATION ........................................................................... . 
11.2 PERFORMANCE ................................................................................. . 
11.3 USE OF INVESTIGATIONAL MATERIALS ................................... . 
11.4 CASE REPORT FORMS ..................................................................... . 
11.5 RETENTION AND REVIEW OF RECORDS .................................... . 
11.6 PATIENT CONFIDENTIALITY......................................................... . 
12.0 INVESTIGATOR’S STATEMENT ........................................................ . 
13.0 APPENDICES ......................................................................................... . 
APPENDIX I. ELEMENTS OF INFORMED CONSENT .......................... . 
APPENDIX II. CONTACT INFORMATION ............................................. . 
 
APPENDIX IV. ANTIDEPRESS ANT TREATMENT RESPONSE 
 
 
  
 
 67
67
67
69696970
70
70717171
72
73747476
77
82
85
90
91 
RAP-MD-06 Protocol Page 12 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
 
 
 
 
14.0 LITERATURE CITED ............................................................................ . 
 93
99
103
106110
114 
RAP-MD-06 Protocol Page 13 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

3.1 LIST OF IN-TEXT FIGURES 
 
 Page
Figure 9.1-1. Study Design ........................................................................... . 
 25 
RAP-MD-06 Protocol Page 14 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
4.0 LIST OF ABBREVIATIONS
ADT antidepressant therapy
AE adverse event
ALT alanine aminotransferase 
AST aspartate aminotransferase
ATRQ Antidepressant Treatment Response Questionnaire
β-hCG beta-human chorionic gonadotropin
BMI body mass index
BP blood pressure
BPRS+ Brief Psychiatric Rating Scale –Positive Symptoms Subscale
CADSS Clinician Administered Dissociative States Scale
CFR Code of Federal Regulations
DALY disability-adjusted life- year
DBTP double-blind treatment period
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSST Digit Symbol Substitution Test
ECG electrocardiogram, electrocardiographic
eCRF electronic case report form
ECT electroconvulsive therapy
EDC electronic data capture
ET early termination
FDA Food and Drug Administration
FR Federal Register
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act 
HIV human immunodeficiency virus
ICF informed consent form 
RAP-MD-06 Protocol Page 15 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

ICH International Conference on Harmonisation 
IND Investigational New Drug (application)
IP investigational product
IRB institutional review board
ITT intent-to-treat
IV intravenous (ly)
IWRS interactive web response system
MADRS Montgomery -Åsberg Depression Rating Scale
MDD major depressive disorder
NEAE newly emergent adverse event
NMDAR N-methyl-D-aspartate receptor
OLTP open-label treatment period
PCS potentially clinically significant
PID patient identification
PRN as needed
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using the Bazett formula 
(QTcB=QT/[RR]½)
QTcF QT interval corrected for heart rate using the Fridericia formula 
(QTcF=QT/[RR]⅓)
SAE serious adverse event
SAP Statistical Analysis Plan
SCID Structured Clinical Interv iew for Diagnostic Statistic Manual of Mental Health 
Disorders, Fifth Edition
SD standard deviation
SDC Symbol Digit Coding
SDMT Symbol Digit Modalities Test
SNRI selective serotonin and norepinephrine reuptake inhibitor
SOC system organ class
SSRI selective serotonin reuptake inhibitor
TEAE treatment -emergent adverse event
UDS urine drug screen
ULN upper limit of normal 
RAP-MD-06 Protocol Page 16 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
5.0 ETHICAL CONSIDERATIO NS
5.1 INSTITUTIONAL REVIEW BOARD
Approval b y the Institutional Review Board (I RB) beforethe start of the study  will be the 
responsibility  of the Investigator . A copy of the approval letter will be supplied to the 
Sponsoralong with a roster of IRB members or theUSDepartment of Health and Human 
Servicesgeneral assurance number . During the course of the stud y, the Investigator will 
provide timely and accurate reports to the IRB on the progress of the study , at intervals 
not exceeding 1 year (or as appropriate), and will notify  the IRB of serious adverse events 
(SAEs) or other significant saf ety findings . The study  protocol, informed consent form
(ICF), information sheet advertisements, and amendments (if any ) will be approved b y 
the IRBs at thestudy centersin conformance with the US CFR, Title 21, Part 56.
5.2 ETHIC ALCONDUCT OF THE STUDY
This clinical study will beconducted in accordance with the ethical principles that have 
their origins in the Declaration of Helsinki .
This clinical study  will comp lywith the ICH Guidance on General Considerations for 
Clinical Trials (I CH-E8; 62FR66113, 17 Dec 1997) and GCP (ICH-E6; 62 FR 25692, 
09 May 1997), as well as the US CFR , Part 312.
5.3 PATIENT INFORMATION AND INFORMED CONSENT
After being given an explanation of the stud y and before participating in any stud y 
procedures, each patient must provide writte n informed consent (in compliance with 
21 CFR, Parts 50 and 312) and HIPAA authorization. 
Each patient will read and sign an ICF and/or other authorization form as per local 
regulations; each patient will be made aware that he or she may  withdraw from the study 
at any time.
The ICF contains all the elements of informed consent listed in Appendix I of this 
protocol. Signed copies of the I CF and the HIPAA or other locall y applicable form will 
be given to the patient, and both documents will be placed in the Investigator’s study  
files. 
RAP-MD-06 Protocol Page 17 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
6.0 INVESTIGATORS AND ST UDY ADMINISTRATIVE 
STRUCTURE
This study  will be performed at approximately  105 to 110 study  centersin the United 
States.
The Investigator is responsible for ensuring that the investigation is conducted accor ding 
to the signed Investigator statement, the investigational plan, GCP guidelines, and 
applicable regulations; for protecting the rights, safety, and welfare of patients under the Investigator’s care; and for the control of investigational products underinvestigation. An 
investigator shall obtain the informed consent for each patient prior to the patient enrolling in the stud y and/or prior to participating in any stud y-related activity . 
The Investigator at each study  center must meet his or her obligati ons to the patients, 
ethics committee, Sponsor, and regulatory  authorities by  maintaining oversight and 
control of the study ’s conduct and the study  staff. It is the responsibility  of the 
Investigator to ensure that any  and all delegated duties be assigned to qualified staff b y 
education, experience, and licensure (in accordance with local regulations) and that the Investigator oversight is documented and assessment of staff capabilities and performance is consistent with the study investigational plan. The Investigator at each 
study center will be responsible for the management of the study, including maintaining 
the study file and the patient records, corresponding with the IRB, and completing the 
electronic case report forms (eCRFs). 
RAP-MD-06 Protocol Page 18 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
7.0 INTRODUCTION
Disease B urden of Major Depressive Disorder
Major depressive disorder ( MDD)is a highly disabling, serious condition which is 
associated with significant morbidity  and mortality . MDD manifests as a major 
depressive episode (which may  be singular or recurrent) in w hich the affected individual 
experiences 1) depressed mood, or 2) loss of interest or pleasure (as well as other 
symptoms) for most of the day , nearly every day, for at least 2 weeks. MDD affects 
approximately  14.8 million American adults, or about 6.7% of the US population 
18years of age and older, in a given year (Kessler et al, 2005 ). Worldwide, about 15% of 
the adult population is at lifetime risk of developing MDD ( Kessler et al, 1994 ). 
Depression may  cause serious, long -lasting symptoms and often di srupts a person’s 
ability to perform routine tasks. I n 2000, unipolar depressive disorders were by  far the 
leading cause (11.9%) of worldwide years of life lived with disability  
(World Health Organization, 2001), and the total economic burden of treating depression 
in the United States was $83.1 billion, with workplace costs, including missed day s and 
lack of productivity  due to illness, accounting for most of the total economic burden 
(62%). Other economic burdens in 2000 included $26.1 billion (31%) for treatment costs 
and $5.4 billion (7%) for suicide-related costs (Greenberg et al, 2003 ). 
MDD is a leading cause of disability in the United States ( Murray et al, 2013). Moreover, 
MDD is known to be a significant risk factor for suicide and ischemic heart disease, as it 
accounted for 16 million of the disability -adjusted life -years (DALYs) associated with 
suicide and 4 million of the DALYs associated with ischemic heart disease. Research has shown that untreated depression has both a functional (social and work role) as well as a 
neuroanatomical (hippocampal shrinkage) effect on the patient ( Videbech and Ravnkilde, 
2004). Given the disease burden and link to suicidality  as well as increased mortality  with 
other comorbid conditions, MDD is a serious and life -threatening condition which is a 
leading cause of disability in the world. 
RAP-MD-06 Protocol Page 19 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Norepinephrine 
Reuptake Inhibitors in Major Depressive Disorder
Selective serotonin reuptake inhibitors (SSRI s) and selective serotonin and 
norepinephrine reuptake inhibitors (SNRI s) currently  represent the first line of treatment 
of depression in the U nited States. Unfortunatel y, a large number of patients do not 
experience therapeutic benefit from these first- lineagents (Rosenzweig -Lipson et al, 
2007). Lack of sufficient response to adequate treatment remains a critical problem in the 
management of patients with MDD. Up to two thirds of patients treated with first- line 
antidepressant monotherapy  do not reach full remission, and as many  as a third become 
treatment resistant ( Fava and Davidson, 1996; Trivedi et al, 2006 ). Not achieving 
remission has been shown to be predictive of poorer ps ychosocial functioning, higher 
rates of relapse, and higher rates of rehospital ization (McIntyre and O’Donovan, 2004 ). 
The results of the STAR*D study  suggest that with successive failures of treatment, 
patients are less and less likely  to respond to subsequent treatment, and those who do 
respond are more likel y to relapse ( Rush et al, 2006). Present strategies available to treat 
patients who do not respond to first- line antidepressant monotherap y include switching of 
antidepressant (either within or between classes); combination therap y in which multiple 
antidepressants are used sim ultaneously ; augmentation of ongoing antidepressant 
monotherap y with adjunctive use of drugs such as mood stabilizers or atypical 
antipsychotics (Boland and Keller, 2006 );and the use of nonpharmacologic treatments 
including ps ychotherap y and phototherap y,vagus nerve stimulation, transcranial 
magnetic stimulation, and electroconvulsive therapy (ECT). 
Existing antidepressants have a number of limitations, leading to considerable unmet medical need in the effective treatment of MDD, with up to 50% of patien ts with MDD 
having an inadequate response or failing current antidepressant therap y (ADT). Currentl y 
available first -line antidepressants (SSRI s, SNRIs) ty pically take 3 to 4 weeks or more of 
continuous daily  dosing to relieve s ymptoms of MDD and are assoc iated with side effects 
related to their pharmacological mechanisms of action (sexual dy sfunction, weight gain, 
jitteriness, sleep disturbances), which are further associated with poor patient compliance (Masand 2003, Ashton et al, 2005 ). Patients often ex perience undesirable side effects 
before they  experience an improvement in depressive sy mptoms, which could lead to 
premature discontinuation of therap y. Taken together, these factors define significant 
areas for improvement of ADT.  
RAP-MD-06 Protocol Page 20 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Patients vary  greatly in their response to antidepressants and it is not possible to reliably  
predict whether an individual patient will respond to a given antidepressant. This leads to 
clinicians often using a trial- and-error approach to identify  an effective antidepressant. 
Due to the gradual development of the full therapeutic effect of currently  available 
antidepressants, each antidepressant needs to be administered for 4 weeks or longer in order to determine the individual therapeutic benefit, making the process of finding an 
effective antidepressant a length y process for patients who are often severely depressed 
and at a high risk for suicide. Clearl y a drug that could induce a rapid antidepressant 
effect would represent a major advancement for these patients.
Atypical Antipsychotics as Adjunctive Therapy in Major Depressive DisorderThe available treatments for adjunctive therap y in MDD also have substantial safet y and 
efficacy limitations. The drugs currently  approved for use as adjunctive therapy  to 
antidepressants for th e treatment of MDD —namely , the atypical antipsychotics Abilify
®
(aripiprazole), Seroquel XR®(quetiapine fumarate), and Rexulti®(brexpiprazole)—are 
associated with significant adverse reactions, as well as a number of serious warnings and 
precautions. Originall y developed for the treatment of psychotic disorders, these drugs 
share a number of clinically  relevant adverse effects based on their mechanisms of action. 
As all current antipsy chotic agents modulate central dopaminergic s ystems, they  all carry 
a risk of extrap yramidal symptoms such as muscular rigidity, acute d ystonia, as well as 
akathisia, which is a particularly relevant adverse event (AE) that complicates clinical management in a significant number of treated individuals, as high as 45% (Sachdev, 1995). In addition, these compounds are associated with a risk of neuroleptic 
malignant s yndrome and tardive d yskinesia. Depending on their individual 
pharmacological profile, antipsy chotics also carry  a risk for metabolic changes including 
hyperglycemia/diabetes mellitus, dy slipidemia and body  weight gain; blood dy skrasias 
such as leucopenia, neutropenia, and agranulocy tosis; orthostatic hy potension; cognitive 
and motor impairment; cataracts; and insomnia ( Abilify, 2014; Seroquel, 2013; 
Rexulti,2015). The range of clinicall y relevant side effects with antips ychotics has to be 
balanced carefull y against the potential for therapeutic benefits in patients with major 
depression. In this context, it is important to highlight that for the approved aty pical 
antipsychotics the full therapeutic benefit required several weeks of daily  adjunctive 
dosing to become apparent, and in many  patients, adverse effects occurred substantially  
earlier than the mood -alleviating effects of these drugs. 
Furthermore, the drugs c urrently approved for adjunctive treatment of MDD also have 
limited efficacy . The pivotal studies for Abilify , the atypical antips ychotic most 
commonly  used for adjunctive treatment of MDD, showed a delay ed onset of effect 
(1-2weeks), a modest magnitude o f effect (effect sizes were 0.35 -0.39 after 6 weeks of 
repeat dosing) and modest rates of response and remission after 6 weeks of repeat dosing (response rates were 32 -34% and remission rates were 25 -26%) (Berman et al, 2007; 
Marcus et al, 2008 ).  
RAP-MD-06 Protocol Page 21 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Clearly, there is a substantial need for the development of novel treatments with a better 
safety/tolerability  profile and a faster onset of full therapeutic benefit.  Rapastinel has 
initially shown substantially  improved safet y/tolerability  as well as promising e fficacy, in 
both speed of onset and overall magnitude, for adjunctive therap y in MDD. 
Rapastinel as a Novel Approach to Treatment of Major Depressive Disorder
The mechanism of action of rapastinel is entirel y different from that of at ypical 
antipsychotics. Rapastinel is an N -methyl-D-aspartate receptor (NMDAR) modulator 
with a novel and complex pharmacological mechanism of action, acting as a nonselective 
agent at NR2 subunits and display ing properties as a functional partial agonist in a 
number of pharmac ological assay s.  
Rapastinel has demonstrated antidepressant properties in relevant animal models, displays cognitive enhancing properties in treated animals, and facilitates hippocampal 
long-term potentiation of sy naptic transmission in preclinical model s. In contrast to 
ketamine, no signal of abuse liability  was detected in informative animal models. 
Rapastinel is available as an intravenous (IV) formulation only . In twoPhase 2 clinical 
studies in patients with MDD, single IV doses of rapastinel 5 mg/k g and 10 mg/kg have 
been shown to produce marked antidepressant effects within 1 day  that lasted for 
approximately  1 week or longer in responding patients.  These antidepressant effects are 
very similar to ketamine’s effects when administered at a low dose as an infusion.  I n a 
systematic review and meta -analysis of ketamine and other NMDAR antagonists in the 
treatment of major depression, a single infusion of ketamine produced a rapid, y et 
transient antidepressant effect, accompanied b y brief ps ychotomimet ic and dissociative 
effects (Newport et al, 2015 ). 
The available Phase 1 and 2 data demonstrated a favorable safety and tolerability  profile 
of rapastinel .  In contrast to ketamine, rapastinel has not sh own a high likelihood to 
inducepsychotomimetic or dissociative effects in humans so far. 
The purpose of this stud y is to assess the safet y and tolerability of rapastinel when 
administered open-label as an adjunctive treatment at a dose of 450 mg as a short I V 
infusion in patients with MDD.  The stud y is intended to support an application for 
regulatory  approval of rapastinel as adjunctive treatment for MDD. 
RAP-MD-06 Protocol Page 22 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
8.0 STUDY OBJECTIVES
The objective of this study  is to evaluate the long-term safet y andtolerability  of 
rapastinel as adjunctive to ADT in patients with MDD.
Safety Objectives
To evaluate the safet y and tolerability  of rapastinel (450 mg IV weekl y or once every  
2 weeks[biweekly]) as an adjunct to ongoing ADT, as evaluated by  AEs, clinical 
laboratory  measures, ECGs, vita l signs,  
To evaluate the ps ychotomimetic effects of rapastinel (450 mg IV weekl y or once 
every 2 weeks) as an adjunct to ongoing ADT, as measured b y the change from 
baseline in BPRS + at all postdose evalu ations
To evaluate the dissociative effects of rapastinel (450 mg IV weekl y or once every  
2weeks) as an adjunct to ongoing ADT, as measured b y the change from baseline in 
CADSS at all postdose evaluations 
RAP-MD-06 Protocol Page 23 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.0 INVESTIGATIONAL PLAN
9.1 OVERALL STUDY DESIGN AND PLAN: DESCRIPTIO N
Study RAP-MD-06 is a multicenter, open- label study  to evaluate the long -term safet y and 
tolerability  of rapastinel as adjunctive therapy  to ADT in adult patients with MDD who 
either complete dthe RAP-MD-04 Double- blind Treatment Peri od (DBTP) at Visit 1 22
(Week 104, ET) or who do not meet criteria to be randomized in to the DBTP of
RAP-MD-04 and are therefore discontinued from that study.  The enrollment of patients 
who did not participate in RAP -MD-04 (identified as de novoenrollment patients) may  
be considered at somestudy centers if enrollment of rollover patients doesnot meet 
targeted projections and will not be allowed unless specified inan official communication 
fromthe Sponsor .
The study  will be conducted in the following periods:
Up to 2-week screening period
Up to 52- week OLTP
2-week safet y follow-up period
The study  is planned to be terminated when 100 patients have completed the 52 -week 
OLTP. The actual sample size is expected to be larger than 100 patients and some 
patients will have less than 52 weeks of open -label treatment (as many  as 500 patients are 
expected to enter the OLTP of Study  RAP-MD-06).
Figure9.1-1provides the study  design schematic. The schedule of evaluations is 
presented in Section 2.0, and detailed descriptions of the procedures conducted at each 
study visit can be found in Section 9.5. 
RAP-MD-06 Protocol Page 24 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.1.1 Screening
The screening period will occur up to 2 weeks prior to Visit 2:
For patients enrolling from Study  RAP-MD-04, the final visit from that study  (Visit 
122[Week 104, ET]) will serve as Visit 1 in RAP -MD-06. These rollover patients
willreceive the first dose of open-labelinvestigational product ( IP) (ie, rapastinel 
450mg IV)at Visit 1to ensure co ntinuity of treatment. 
Uponproviding written informed consent, de novopatients will enter a screening 
period of up to 14 days. De novopatients will not receive any IP during the screening 
period but must continue their background ADT at the same dose and wash out of 
prohibited medications ( Appendix III ). De novo patients meeting the eligibility  
criteria at the end of Visit 2 (Baseline) will be assigned a treatment by  IWRS and 
enter the OLTP. 
RAP-MD-06 Protocol Page 25 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

All patients will maintain usage of their ADT throughout participation in the study  
(seeSection 9.4.10.1).
9.1.2 Open -label Treatment Period
Approximately  500 patients are planned for enrollment in the OL TP; all patients will 
receive open- label rapastinel at 450 mg IV (adjunctive to ADT) , either weekly  or once 
every 2 weeks, based upon the I nvestigator’s discretion. Patients will skip odd -numbered 
visits ifbeing treated on a biweeklybasis).The once-every-2-weeks schedule can onl y be 
initiated on even -numbered visits in order to maintain the appropriate visit schedule. 
Patients who are on a once -every-2-weeks schedule can be transitioned back to weekl y 
visits at any  visit.
Upon completion of the OLTPat Visit 54 (Week 52, ET) , patients will enter a 2 -week 
safety follow-up periodand will return to the clinic at Visit 55 (Week 54). The maximum 
duration of the study  will be 56 weeks.
The study  will be terminated when 100 patients have completed the 52-week OLTP.
9.1.3 Safety Follow -up Period
All patients who complete or discontinue from the OLTP should enter the 2 -week safet y 
follow-up period.
Additional follow -up visits may  be scheduled within 30 day s, if necessary ,for safety 
reasons.
9.2 DISCUSSION OF STUDY DESIGN, INCLUDING TH E CHOICE 
OF CONTROL GROUPS
The 52-week, open -label study was designed to assess long -term safety  following 
continued adjunctive rapastinel treatment in adult patients with MDD . In this study , 
investigators will enroll patients who completed Study  RAP-MD-04 or, as needed, enroll 
patients 18 through 65 years of age who meet the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM -5) criteria for MDD ( American Psychiatric 
Association, 2013). The MDD diagnosis will be confirmed using the Modified Structured 
Clinical Interview for Diagnostic Statistic Manual of Mental Health Disorders, 
FifthEdition (SCI D). Thesymptoms and severit y of MDD will be assessed using the 
Montgomery -Åsberg Depression Rating Scale ( MADRS)(Section 9.5.1.2.1). 
Study centers will have experience with the study  population and will be encouraged to 
apply available guidelines to minimize patient risk or distress. 
RAP-MD-06 Protocol Page 26 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Dose selection information is presen ted in Section 9.4.6. The planned dosing regimen is 
based on experience from previous rapastinel studies.
The 2-week safet y follow-up period allows continued patient monitoring after IP has 
been discontinued.
9.3 SELECTION OF STUDY POPULATION
9.3.1 Inclusion Criteria
Note: For rollover patients who completed the lead- in study (RAP-MD-04), medical, 
psychiatric, and medication histories from Visit 1 of RAP-MD-04 will be used. For such 
patients, I nclusion Criteria 2, 4, 5, and 6arenot applicable based on participation in 
RAP-MD-04.
To be eligible to participate in the study , patients must meet the following criteria:
1.Written informed consent, obtained from the patient before the initiation of any  
study-specific procedures (Section 5.3)
2.Male or female outpatients who are18 to 65 y ears of age
3.For rollover patient sfromRAP-MD-04, completion of Study  RAP-MD-04 
(eitherOLTP or DBTP) with continued ADT treatment
4.Meet DSM -5 criteria for MDD based on confirmation from the modified SCID, 
with a current major depressive episode of at least 8 weeks and not exceeding 
18 months in durat ion at Visit 1
 
6. Have no more than partial response (< 50% improvement) to ongoing treatment 
with a protocol -allowed ADT   
 
 
 
 
 
  
RAP-MD-06 Protocol Page 27 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
8. If female of childbearing potential, have a negative serum β- human chorionic 
gonadotropin (β -hCG) pregnancy  test at Screening (Visit 1). Because Visit 1 
pregnancy test results will not be available on the day  of Visit 1, rollover patients 
can be discontinued at Visit 2 if Visit 1 pregnancy  test is positive.
9.3.2 Exclusion Criteria
Note:For rollover patients who completed the lead
-in study (RAP-MD-04), medical, 
psychiatric, and medication histories from Visit 1 of the lead- in study will be used
(Exclusion Criteria Nos. 1-8, 12-14, 17, 21- 25, and 27) . Because Visit 1 clinical 
laboratory  or ECG results will not be available on the day  of Visit 1, if there are an y 
safety concerns related to Visit 1 clinical laboratory or ECG results, patients can be 
discontinued at Visit 2.
Patients who meet an y of the following criteria will not be eligibl e to participate in the 
study :
Exclusion criteria to be assessed at Screening ( Visit 1)
Psychiatric and Treatment -Related Criteria:
1.DSM-5-based diagnosis of an y disorder other than MDD that was the primary 
focus of treatment within 6 months before Visit 1. Comorbid generalized anxiety  
disorder, social anxiety  disorder, or specific phobias are acceptable provided they  
play a secondary  role in the balance of s ymptoms and are not the primary  driver 
of treatment decisions. 
2.Lifetime history  of meeting DSM- 5 criteria for:
○Schizophrenia spectrum or other ps ychotic disorder
○Bipolar or related disorder
○Major neurocognitive disorder 
○Neurodevelo pmental disorder of greater than mild severit y or of a severity 
that impacts the patient's ability  to consent, follow study  directions, or 
otherwise safel y participat e in the study
○Dissociative disorder 
RAP-MD-06 Protocol Page 28 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
 
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 29 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.Suicide risk, as determined by  meeting any  of the following criteria:
 
 
 
 
 
 
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 30 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
 
 
 
 
 
 
9.3.3 Removal of Patient s from Therapy or Assessment
A premature discontinuation will occur when a patientwho signed the ICFceases 
participation in the study , regardless of circumstances, 
beforethe completion of the study  
visits and procedures . Patients can be prematurel y discontinued from the study  after 
carefulconsideration for one of the following reasons: 
RAP-MD-06 Protocol Page 31 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

Screen failure (failure to meet inclusion/exclusion criteria)
Pregnancy
Withdrawal of consent
AE
Lack of efficacy
Protocol violation
Noncompliance with IP
Noncompliance with ADT
Lost to follow -up
Study terminated by  Sponsor
Study centerterminated by  Sponsor
Other
All patients who prematurely  discontinue from the study , regardless of cause, should be 
seen for a final assessment at an ET Visit. A f inal assessment will be defined as 
completion of the evaluations scheduled for all patients at Visit 54 (Week 52). All 
patients discontinuing the study  prematurel y should enter the 2 -week safety  follow-up 
period.
Patients who discontinue from the study  and do not return to the study  center for final 
assessments must be requested in writing to return to the study center for a final 
assessment. A cop y of the letter, together with the source documentation, will be kept in 
the Investigator’s files. The reason for premature discontinuation from the study  will be 
recorded on the Study  Termination Page of the eCRF. Study  center staff will be contacted 
by the Sponsor after each premature discontinuation to ensure proper characterization of 
the reason for discontinuation is captured.
9.3.4 Patient Replacement Procedures
Patients in this study  who prematurely discontinue treatment will not be replaced. 
RAP-MD-06 Protocol Page 32 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.4 TREATMENTS
During the OLTP, all eligible patients will receive open -label, once -weekly or onceevery 
2 weeks(biweekly, at Investigator’s discretion) IV rapastinel 450 mg. Patients receiving 
biweekly treatment will skip all odd -numbered visits on the Schedule of Evaluations 
(Section 2.0).
9.4.1 Background Antidepressant Therapy
De novopatients must enter the study  while having no more than partial response (< 50% 
improvement) to ongoing treatment with a protocol-allowed ADT   
 
 
 
 
 
 
Patients entering from StudyRAP-MD-04 will have alread y fulfilled this requirement but 
must continue their background ADT as described below.
Upon entry into the study at Screening/Visit 1, the dosage of the ADT must be held 
constant at a dose in accordance with the respective label throughout participation in 
RAP-MD-06. If a patient experiences an AE, intercurrent illness, or s ymptoms of 
intolerance, heor she will be permitted to stop taking the ADT for a maximum of 
5consecutive day s at the discretion of the Investigator. No other alterations in the ADT 
dose regimen are allowed. If an ADT dose change is required during the study , the 
patient should be discontinued from the study .
Background ADT medication compliance will also be closel y monitored. Compliance 
will be based on patient report. Every effort should be made to have patients bring their 
background ADT to each study  visit for verification o f patient-reported compliance by  
pill count (to the extent possible). 
RAP-MD-06 Protocol Page 33 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.4.2 Treatments Administered
The IPwill only be administered to eligible patients under the supervision of the 
Investigator or identified subinvestigator s or other assigned personnel authorizedto 
administer IV drugs.  IPwill be administer ed in a “slow bolus” injection to an upper 
extremity  vein within approximately  1 to 2 minutes to each stud y patient. The patient 
should not be discharged from the study  center until the Investigator or medically 
qualified subinvestigator determines that the patient is medically  able to leave the stud y 
center(recommended not less than 15 minutes following administration).
9.4.3 Identity of Invest igational Product
Rapastinel 450 mg IV P refilled Syringes:
 
.
 
 
 
 
 
 
The study  center personnel will complete the kit label and attach the tear -off portion from 
the kit label to the source documents.
The prefilled s yringe will be labeled with the protocol number andkit number. The study 
center personnel will write the PID number on the prefilled s yringe associated with the 
kit mentioned above. The prefilled s yringe will not have a tear -off and the label will 
remain on the prefilled sy ringe.
9.4.4 Handling of Investigational Product
The IPmust be stored in a secure area and administered onl y to patients entered into the 
clinical study , at no cost to the patient, in accordance with the conditions specified in this 
protocol.
 
  
RAP-MD-06 Protocol Page 34 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

At the end of the stud y, all IP must be accounted for. In addition, at the end of the study , 
all unused I P and empt y IP packages should be returned to the Sponsor or the local 
distributor at the address provided in the Study  Reference Manual.
9.4.5 Method of Assigning Patient s to Treatment Groups
Patients enrolling from RAP- MD-04 will keep the same PID number that was assigned in 
that study . 
For de novopatients (new patients who did not participate in RAP -MD-04), after a 
patient signs the ICF at Screening (Visit 1), study personnel will register the patient in the 
IWRS, and the s ystem will assign the patient a sequential PI D number. 
 
 
The IP will be labeled with medication kit numbers.  The I WRS will provide the study  
center with the specific medication kit number(s) for each patient.  Study  centers will 
dispense I Paccording to the I WRS instructions.  Study  centers will also log onto the 
IWRS at subsequent visits to obtain a study  medication kit number for dispensing IP. 
Study centers will receive the I WRS confirmation notifications for each transaction. All 
notifications are to be maintained with the study  source documents.
9.4.6 Selection of Dos ages in the Study
A rapastinel dose of 450 mg was chosen for this study  based on results from 2 Phase 2 
clinical studies of patients with MDD in which single IV doses of rapastinel 5 mg/kg and 
10mg/kg were shown to produce marked antidepressant effects within 1 day  that lasted 
approximately  1 week or longer in responding patients .The 450-mg IV dose is expected 
to provide an appropriate dosefor most patients based upon t he Phase 2 study  results. 
The use of a single -unit dose is intended to aid in the simplicity  of administration and 
avoid dosing errors.
RAP-MD-04 also assessed both weekl y and biweekly  dosing regimens. While the 
GLYX13 -C-202 study  also assessed the effect of weekl y and biweekl y administration 
after initial stabilization, and found no differences, the comparison was onl y carried out 
for 6 weeks in that study .Assessing a less frequent dosing regimen over the more 
substantial time period of 26 weeks to 2 yearsin RAP-MD-04 followed b y an additional 
52 weeks of treatment in RAP -MD-06is expected to y ield a better understanding of the 
long-term safet y characteristics of rapastinel treatment and allow proper guidance to 
physicians regarding treatment bey ond initial stabilization. 
RAP-MD-06 Protocol Page 35 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.4.7 Selection and Timing of Dose for Each Patient
The IP will be administered IV using the assigned single -use prefilled sy ringes either 
weekly or biweekl y based on the discretion of the Investigator , per the Schedule of 
Evaluations (Section 2.0) . A patient may  be switched between weekly  and biweekl y 
treatment at an y time during the OLTP . For patients on a biweekl y schedule, only 
odd-numbered visits during the OL TPmay be skipped.
9.4.7.1 Screening Period
For patients enrolling from RAP -MD-04, the final visit from that study  (Visit 122
[Week104, ET]) will serve as Visit 1 in this study , after written consent is obtained. 
Rollover patients will receive open -label IPat Visit 1 to ensure continuity  of treatment.
For de novopatients, a t Visit 1, after written consent is obtained, patients will enter a 
screening period of up to 14 day s.No IP is administered to de novopatients during the 
screening period; however, patients must continue their background ADT at a stable 
dose.During this time de novo patients will wash out of prohibited medications, per 
Appendix III .
9.4.7.2 Open-label Treatment Period
Patients enrolling from RAP -MD-04 who meet all eligibility  criteria at Screening 
(Visit1) will receive IP at Visit 1, and patients who continue to meet all the eligibility  
criteria for participation in the study at Baseline (Visit 2) will continue to receive I P 
during the OLTP.
De novopatients who meet all eligibility  criteria at Screening (Visit 1) and who continue 
to meet all the eligibility  criteria for participation in the study  atBaseline(Visit 2)will be 
assigned an IP kit number via I WRS at Visit 2.
All eligible patients will receive rapastinel 450 mg IVfrom a prefilled single- dose 
syringe at Visits 2 through Visit 53 (Week 51).
9.4.7.3 Safety Follow -up Period
Patients who complete the OLTP or patients who prematurel y discontinue from the study 
should enter the 2 -week safety follow-up period, returning to the clinic for Visit 55 
(Week 54) .No IP is administered during the safety  follow-up period.  P atients’ 
background ADT may  be modified as deemed appropriate by  the Investigator.
9.4.8 Blind ing
Not applicable 
RAP-MD-06 Protocol Page 36 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.4.9 Unblinding
Not applicable
9.4.10 P rior and Concomitant Therapy
A list of example medications that are allowed and not allowed as concomitant 
medications for either episodic or chronic use is provided in Appendix III . 
For de novopatients, m edication history  (psychotropic medication history  during the 
previous 5 y earsand all other medications during the past 12 months) will be recorded at 
Screening (Visit 1) in the eCRF. Thereafter, an y changes in concomitant medications or 
any new medications added will be recorded in the eCRF.
9 1
 
 
 
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 37 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
9 2
 
 
 
 
 
.
9.4.11 Other Restrictions
9.4.11.1 Alcohol
It is recommended that patients abstain from alcohol consumption during the study.
9.4.11.2 Contraception
For purposes of this study, females will be considered of childbearing potential unless 
they are naturall y postmenopausal or permanentl y sterilized (ie, hy sterectomy ).  Natural 
menopause is defined as the permanent cessation of menstrual periods, dete rmined 
retrospectivel y after a woman has experienced 12 months of amenorrhea without any  
other obvious pathological or phy siological cause.   
RAP-MD-06 Protocol Page 38 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

For women of childbearing potential who may  participate in the study , the following 
methods of contraception, if p roperly used, are generall y considered reliable: hormonal 
contraceptives (ie, oral, patch, injection, implant), male condom with intravaginal 
spermicide, diaphragm or cervical cap with spermicide, vaginal contraceptive ring, intrauterine device, surgical s terilization (bilateral tubal ligation, bilateral salpingectomy ), 
vasectomized partner, or sexual abstinence.
The Investigator and each patient will determine the appropriate method of contraception 
for the patient during the participation in the study .
See Section 9.5.2.3 for pregnancy  reporting procedures.
9.4.12 Monitoring Treatment Compliance
IP compliance during any period will be closel y monitored by  capturing the date and time 
of each injection of IP.  If a scheduled injection does not occur, the Sponsor must be notified and the reason captured in the eCRF.
Background ADT compliance will als o be closel y monitored. Background ADT 
medication compliance will be based on patient report. Every effort should be made to 
have patients bring their background ADT to each study  visit for verification of 
patient-reported compliance by  pill count (to the extent possible).  Missed doses or other 
changes in the dose of ADT and the reason should be captured in the eCRF .
9.4.13 Treatment After Discontinuation
Patients whose MDD symptoms worsen or are determined by the Investigator not to be 
adequatel y controlled prio r to completing the OLTP will be allowed to discontinue the 
study and start appropriate treatment at the Investigator’s discretion. This new treatment 
will not be provided by  the Sponsor. Patients who initiate a new treatment must be 
discontinued from the study.
9.5 EFFICACY AND SAFETY VARIABLES
9.5.1 Diagnostic and Efficacy Assessments
9.5.1.1 Diagnostic Assessments
The SCIDwill be administered during the screening interviews by  a psychiatrist,doctoral 
level clinical ps ychologist , or other clinician who has extensive professionaltraining and 
experience in the diagnosis of mental illness and who meets the training requirements and 
qualifications standards set by  the Sponsor and rater training vendor. 
RAP-MD-06 Protocol Page 39 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9 2
 
 
 
 
 
 
 
 
 
 
 
 
 
9.5.2 Safety Assessments
Patients must be evaluated by  a physician or an appropriatel y-trained healthcare 
professional a t every visit and the evaluation must be documented. The procedures 
discussed in the following sections will be completed at the 
designated visits.
9.5.2.1 Adverse Events
An AE is an y untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily  have to have a 
causal relationship with this treatment. An AE can therefore be any  unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH -E2A). 
RAP-MD-06 Protocol Page 40 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

For the purpose of the study  center’sdata collection responsibilities, any  untoward event 
that was reported from the time the patient signed the ICF until 30days after the final 
protocol-defined stud y visit or the last known dose of I P (if the final visit does not occur) 
is to be considered an AE.
Examples of AEs are as follows:
Changes in the general condition of the patient
Subjective sy mptoms offered by  or elicited from the patient
Objective signs observed by  the Investigator or other study  center personnel
All diseases that occur after signing informed consent, including an y change in 
severity or frequency of pre -existing disease
All clinically  relevant abnormalities in laboratory  values or clinicall y relevant 
physical findings that occur during the study  schedule
Please note that medical procedures scheduled prior to consenting, but occurring during 
the study should not be ca ptured as AEs, but should be listed in the medical history  if 
related to a pre -existing condition.
9.5.2.1.1 Causality Assessment
For each AE, the Investigator must provide an assessment of causal relationship to the I P. 
The causality  assessment must be recorded on the appropriate AE reporting page of the 
patient’s eCRF. Causal relationship must be assessed by answering the following 
question:
Is there a reasonable possibility  the IP caused the event?
Yes: There is evidence to suggest a causal relatio nship between th e IP and AE, ie:
○There is a reasonable temporal relationship between the I P and the event, and/or 
○The event is unlikel y to be attributed to underl ying/concurrent disease or other 
factors, and/or
○Positive dechallenge and/or rechallenge exist
No: There is no evidence to suggest a causal relationship between the IP and AE, 
ie:
○There is no reasonable temporal relationship between the IP and the event, or 
RAP-MD-06 Protocol Page 41 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
○The patient did not take the I P, or
○The event is likel y to be attributed to underl ying/concurrent disease or other 
factors, or
○The event is commonl y occurring in the (stud y) population independent of IP 
exposure
9.5.2.1.2 Severity Assessment
The Investigator will provide an assessment of the severit y of each AE b y recording a 
severity rating on the appropriate AE report ing page of the patient’s eCRF. Severity,
which is a description of the intensity of manifestation of the AE, is distinct from 
seriousness, which implies a patient outcome or AE -required treatment measure 
associated with a threat to life or functionalit y (Section 9.5.2.1.3). Severit y will be 
assessed according to the following scale:
Mild: A type of AE that is usually  transient and may  require only  minimal 
treatment or therapeutic intervention. The event does not generally  
interfere with usual activities of daily  living.
Moderate: A type of AE that is usually  alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily  living, 
causing discomfort, but poses no significant or permanent risk of harm to 
the research participant.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y 
affects clinical status, or may require intensive therapeutic intervention.
9.5.2.1.3 Serious Adverse Events
An SAE is any  untoward medical occurrence that at any  dose:
Results in death
Is life threatening
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity , or
Is a congenital anomal y/birth defect 
RAP-MD-06 Protocol Page 42 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Important medical events that may  not result in death, be life threatening, or require 
hospitalization may  be considered serious when, based on appropriate medical judgment, 
they may jeopardize the patient and may  require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dy scrasias or convulsions that do not result in patient hospitalization, or the 
development of IP dependency  or drug abuse.
Emergency  room visits that do not result in hospitalization should be evaluated for one of 
the other serious outcomes to determine whether they  qualify as SAEs.
Preplanned hospitalizations (eg, elective procedures for pre- existing conditions that did 
not worsen, such as cosmetic surgery  and hysterectomy ) are excluded from SAE 
reporting.
9.5.2.1.4 Reporting Adverse Events and Serious Adverse Events
At each visit, patients are to be queried regarding any  AEs or SAEs that have occurred 
since the previous visit. Patients will be asked to volunteer information with a nonleading 
question such as, “How do y ou feel since your last visit?” Stu dy center personnel will 
record all pertinent information in the patient’s eCRF. 
All AEs must be recorded on the appropriate AE reporting page of the patient’s eCRF 
whether or not they  are considered causally  related to the I P.
For every  AE, the Investigator must:
Provide an assessment of the seriousness of the event (ie, is it an SAE?), as well as 
the severit y and casual relationship
Document all actions taken with regard to the I P
Detail any other treatment measures taken for the AE
Document the outcome of the AE
In addition, patients are to be reminded, as described in the I CF and in accordance with 
Section 9.5.2.1, to notify  study centerpersonnel of any  AEs occurring during the 30- day 
poststudy period. Any  AEs reported b y the patient (or patient representative) during this 
period are to be recorded in original source documents. AEsare also to be recorded in the 
eCRF if at least one of the following conditions ismet: 1) the event meets the criteria for 
an SAE (see Section 9.5.2.1.3 and Section 9.5.2.1.4), and/or 2) the event is judged by the 
Investigator to be potentially  causally related to I P. 
RAP-MD-06 Protocol Page 43 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Any AEs that are ongoing at the time of the final protocol- defined stud y visit will be 
followed until the condition returns to prestud y status, has resolved or stabilized, or can 
be explained as being unrelated to the IP. If a follow -up visit is deemed necessary  for 
appropriate safet y surveillance, it will take place within 30 days of the final protocol-
defined stud y visit.
9.5.2.2 Immediate Reporting of Serious Adverse Events and Events of 
Special Interest
The Sponsor is required to inform worldwide regulatory  authorities of SAEs that meet 
specific criteria. Therefore, the Sponsor must be notified immediately  regarding an y SAE 
that occurs after informed consent is obtained.
Within 24 hours of learning of an y AE that meets one of the criteria for an SAE, the 
study center personnel must report the event to Global Drug Safet y on the SAE Form for 
Clinical Trials. The Study Physician may  also be notified by  telephone.
If, during follow -up, any nonserious AE worsens and eventuall y meets the criteria for an 
SAE, that AE should be recorded as a new SAE. The study  center must transmit the SAE Form for Clinical Trials to th e SAE fax number 
provided at the end of this section . Even if an initial report is made by telephone, the SAE 
Form for Clinical Trials completed with all available details must still be faxed within 
24hours of knowledge of the event at the stud y center.
Supplemental information should be submitted as soon as available and may include 
laboratory  results, radiology  reports, progress notes, hospital admission and emergency  
room notes, holding and observation notes, discharge summaries, autops y reports, and 
death certificates.
The Investigator is expected to take all therapeutic measures necessary  for resolution of 
the SAE. Any medications or procedures necessary  for treatment of the SAE must be 
recorded on the appropriate pages of the patient’s eCRF. All SAEs are to be followed b y 
the study staff until resolution or until the SAE is deemed stable. The Sponsor may 
contact the study center to solicit additional information or follow up on the event.
Fax the SAE Form for Clinical Trials to the Sponsor . 
RAP-MD-06 Protocol Page 44 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.5.2.3 Reporting of Pregnancies Occurring During the Study
Study center personnel must report every  pregnancy  from the time the patient signs the 
ICFuntil 30 day s after the last dose of IP. Within 24 hours of learning of the pregnancy , 
the study center personnel must report the event to Global Drug Safet y on the Clinical 
Trial Pregnancy  Form and fax it to the SAE/pregnancy  fax number provided in 
Section 9.5.2.2, even if no AE has occurred. Pregnancies in female partners of male 
patients occurring during the timeframe described above must also be reported. 
Any pregnancy  of a patient treated with IP must be followed to term and the outcome 
reported b y completing a follow -up Clinical Trial Pregnancy  Form. If the pregnancy is 
associated with an SAE (eg, if the mother is hospitalized for hemorrhage), a separate 
SAE Form for Clinical Trials must be filed as described in Section 9.5.2.2 with the 
appropriate serious criterion (eg, hospitalization) indicated in addition to the pregnancy  
form.
9.5.2.4 Potential Hy’s Law Cases
The criteria for potential Hy ’s Law cases are as follows:
ALT or AST ≥ 3 × ULN and 
Total bilirubin ≥ 2 × ULN and 
Alkaline phosphatase < 2 × ULN
Study center personnel must report every  patient who meets these potential criteria. 
Typically, all 3 anal ytes will be obtained from the same sample, but they  may come from 
multiple samples taken within a 24- hour period. This requirement applies from the time 
the ICF is signed for the study  until 30 day s after the final protocol- defined study  visit or 
the last known dose of IP (if the final visit does not occur). 
A laboratory alert for potential Hy ’sLaw cases will be in place, and the laboratory  must 
notify investigators and the Sponsor immediately  when the above criteria have been met. 
A potential Hy ’s Law case must be faxed to the Sponsor on an AE of Interest Form as 
soon as possible (within 24 hours of learning of the potential Hy ’s Law) to the 
SAE/preg nancy fax number stated in Section 9.5.2.2, even if no AE has occurred. The 
eCRF for potential Hy ’s Law cases must be completed within 7 calendar da ys. Every 
effort to determine the cause of the liver enz yme abnormalities must be made, and close 
monitoring should be initiated in conjunction with the Study  Physician and in accordance 
with the FDA Guidance for Industry : Drug Induced L iver Injury  -Pre-Marketing Clinical 
Evaluation, July  2009. 
RAP-MD-06 Protocol Page 45 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.5.2.5 Clinical Laboratory Determinations
Blood and urine samples for clinical laboratory  tests will be collected as detailed in the 
Schedule of Evaluations ( Section 2.0). During screening, the Investigator will assess the
clinical significance of any values that are outside the reference ranges provided by  the 
central laboratory ; patients with abnormalities judged to be clinicall y significant will be 
excluded from the study .
Patients will be a sked to fast overnight or for at least 8 hours before arriving at the stud y 
center for appointments involving the collection of clinical laboratory  blood tests.
The following clinical laboratory  levels will be measured:
Hematology: Absolute and differential white blood cell count, ery throcyte 
count, hemoglobin, hematocrit, platelet count, and red blood cell 
indices (mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration)
Chemistry: Sodium, potassium, calcium, chloride, bicarbonate, magnesium,gamma glutam yl transferase,phosphate, glucose, blood urea 
nitrogen, creatinine, creatine phosphokinase, total protein, 
alkaline phosphatase, albumin, bilirubin (total; direct; indirect), ALT, AST, total cholesterol, low -density lipoprotein, high- density 
lipoprotein, and trigl ycerides
HbA1c and fasting insulin: As specified in the Schedule of Evaluations ( Section 2.0)
Urinalysis: Specific gravit y, pH, protein, glucose, ketones, and blood
Thyroid function: Thyroid function test at Screening (Visit 1) and pe riodically  as 
specified in the Schedule of Evaluations ( Section 2.0)
UDS: Benzoylecgonine (cocaine), barbiturates, amphetamines, 
benzodiazepines, cannabinoids, opiates, methadone, phencyclidine, performed at Screening (Visit 1) , and periodicall y 
as specified in the Schedule of Evaluations ( Section2.0)(and at 
Investigator’s discretion)
Serum β -hCG: Serum β-hCG will be performed at Screening (Visit 1) and 
periodicall y as specified in the Schedule of Evaluations 
(Section 2.0)(and at Investigator’s discretion) 
RAP-MD-06 Protocol Page 46 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Hepatitis screening: Hepatitis–C virus antibody , hepatitis –B surface antigen, and 
hepatitis-B core antibod y total will be tested. Reflex hepatitis -B 
core antibod y IgM will be performed for all hepatitis–B core 
antibody total positive or reactive results. Positive test results will 
be sent for confirmation testing. Hepatitis screening is to be 
conducted at Screening (Visit 1)on de novo patients only  
(newpatients who did not participate in RAP -MD-04).
Clinical laboratory  tests may  be performed under special circumstances (and at 
Investigator’s discretion).
A negative UDS (except for benzodiazepines if prescribed b y the Investigator as per the 
protocol) is required before Baseline (Visit 2) for the patient to continue in th e study. A 
UDS may be performed at any  time during the study  at the discretion of the I nvestigator. 
A patient with a positive UDS for benzodiazepines or opiates at an y visit may be allowed 
to continue in the study  provided the patient has been prescribed t he medication and it is 
being used for legitimate medical purpose in the Investigator’s judgment.Serum pregnancy  test will be perform ed as specified in the Schedule of Evaluations
(Section 2.0).Positive results on the pregnancy  test at Screening (Visit 1) will exclude 
patients from participating in the stud y. Positive pregnancy test results during the stud y 
will result in patient termination from the study .
Other laboratory  assessments may  be repeated at any  visit if there was an abnormal 
finding at the most recent previous evaluation or if additional information is clinically  
necessary  to appropriately  evaluate the patient’s current condition, follow up, and/or 
manage an adverse experience. A central laboratory  will be used to evaluate all urine and blood samples, which will be 
collected, processed, and stored according to the instructions provided by  the laboratory . 
9.5.2.6 Vital Signs
Vital signs (pulse rate, s ystolic and diastolic BP, oral or t ympanic temperature , and body 
weight) will be assessed at every  visit during the OL TP. Height will be assessed at Visit 1
for de novopatientsonly(Section 2.0).
BP and radial pulse rate will be measured in the supine position followed by  the standing 
position. The standing measurements should be assessed after a sufficient amount of time 
has been elapsed to allow the BP to equilibrate in the standing state.
Radial pulse rate should be measured after BP measurements. BP may  be measured 
manually or by machine, but radial pulse rate should only  be measured manually  and for 
a sufficient time to acquire an accurate measurement. 
RAP-MD-06 Protocol Page 47 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Patients should be instructed not to wear clothing with tight sleeves when they  come for 
clinic visits. Additionally , patients shoul d be kept as calm and undisturbed as possible 
while BP and pulse rate measurements are taken (eg, there should be no talking while the 
BP is being measured). The same arm and BP cuff (appropriate to the arm circumference) should be used for all BP measurements.
Whenever possible, the patient’s weight will be measured at the same time of day ; 
patients should wear their usual indoor clothing, but take off their jacket and shoes. For 
each patient, body  weight should be determined using the same equipment durin g the 
study after ensuring its proper calibration.
9.5.2.7 Electrocardiograms
A 12-lead ECG will be performed at the visits outlined in the Schedule of Evaluations
(Section 2.0). The ECGs will be performed and electronicall y transmitted to a central 
ECG laboratory for analysis according to the instructions provided by the central ECG 
laboratory . Measurements (in msec) will be recorded for the following parameters: 
PRinterval, QRS duration, and uncorrected QT interval . QTcB (Bazett corrected 
QTinterval) and QTcF ( Fridericia corrected QT interval) will be calculated. 
The overall interpretation and determination of the clinical relevance of ECG findings using the central ECG interpretation laboratory  report will be the responsibility  of the 
Investigator and will be recorded in the patient’s eCRF. For eligibility  criteria, the values 
reported on the central ECG interpretation report will be used (not the values printed on 
the tracing itself).
9 8
 
 
  
RAP-MD-06 Protocol Page 48 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.5.2.8.3 Brief Psychiatric Rating Scale -Positive S
ymptoms Subscale 
The BPRS is an 18- item evaluation that assesses psy chiatric symptoms and unusual 
behavior ( Overall and Gorham, 1962).  The BPRS+ is a subset of the BPRS that assesses 
4 components of the BPRS +related to the degree of psy chosis: Conceptual 
Disorganization, Suspiciousness, Hallucinatory  Behavior , and Unusual Thought Content. 
Only the 4 items of the BPRS+ subscale will be collected and analy zed. The BPRS+ will 
be administered b y the Investigator or designee with extensive professional training and 
experience in assessing mental illness. 
RAP-MD-06 Protocol Page 49 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.5.2.8.4 Clinician Administered Di ssociative States Scale 
The ClinicianAdministered Dissociative States Scale (CADSS) is a 28- item 
clinician-administered measure of perceptual, behavioral, and attentional alterations 
occurring during active dissociative experiences composed of 23 subjective self -reported 
and 5 objective observer -reported ratings, each scored from 0 (not at all) to 4 (extremely ). 
Only the 23 subjective ite ms will be collected and anal yzed. The CADSS provides a 
validated assessment of dissociative states sensitive to change over time and amenable to 
repeated measures ( Bremner et al, 1998). The CADSS will be administered by  the 
Investigator or designee with e xtensive professional training and experience in assessing 
mental illness.
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 50 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9 1  
 
 
 
 
 
 
 
 
 
 
9.5.6 Schedu le of Assessments
The schedule of study  procedures and assessments is tabulated by  visit in the Schedule of 
Evaluations in Section 2.0.
 The descriptions of the procedures to be performed at each 
visit are provided in the following sections.
9 1
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 51 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 52 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
9 2
 
 
  
RAP-MD-06 Protocol Page 53 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
9 3  
 
 
 
 
 
 
 
9 4 
RAP-MD-06 Protocol Page 54 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
9 5
 
  
RAP-MD-06 Protocol Page 55 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
 
 
9 6
 
 
 
 
  
RAP-MD-06 Protocol Page 56 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9 7
 
 
 
 
 
  
RAP-MD-06 Protocol Page 57 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
 
9.5.6.9 Unscheduled Visits
Unscheduled visits can be performed if safet y concerns arise and at the discretion of the 
Investigator. Additional examinations may  be performed as necessary  to ensure the safet y 
and well-being of the patients during the study .
9.6 DATA QUALITY ASSURANCE
9.6.1 Data Monitoring
Before an y patient enters the study, a representative of the Sponsor will meet with the 
Investigator and the study center staff to review the procedures to be followed during the 
study. Electronic data capture (EDC) functionality  training is provided via 
computer -based training to train investigators and authorized designees on recording the 
data in the eCRFs using the EDC sy stem. After the first patient is enrolled, the Sponsor 
representative, a Regional Site Manager or designee, will periodicall y monitor the 
progress of the stud y by conducting on -site visits. This Regional Site Manager or 
designee will revie w query statuses remotel y, possibly  warranting more frequent 
communication and/or study  center visits with the I nvestigator and the study  center staff. 
The Investigator will make available to the Regional Site Manager or designee source 
documents (written notes and electronic medical records, if used), signed consent forms, 
and all other stud y-related documents. The Investigator and the study  center staff will be 
responsible for data entry of patient data into the eCRFs via the EDC sy stem, resolving 
data queries generated via the EDC s ystem and providing missing or corrected data. The 
Investigator or designee will be responsible for approving all changes performed on the data, and endorsing the patient data within the EDC sy stem. This approval method will 
include appl ying an electronic signature linked to a uniquely  assigned username and 
password that together will represent a traditional handwritten signature used in the past. 
RAP-MD-06 Protocol Page 58 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.6.2 Data Recording and Documentation
Data collection will involve the use of the EDC s ystem, to which only  authorized 
personnel will have access. Patient’s data are to be entered into the EDC system b y the 
Investigator or designee using their assigned EDC user account. After data entry into the 
EDC system by the Investigator or designee, a combination of manual and programmatic 
edit checks will be used to review the data for completeness, logic, and adherence to study protocol. As a result of these edit checks, data monitoring, and reviews, queries 
may be electronicall y issued to the study c enter and should be answered electronicall y via 
the EDC sy stem.
Each query  will carry  identifying information (assigned username, date, and time) to 
assist the Sponsor and the Investigator on the origin of the data clarification request and the response pr ovided by the I nvestigator. All data changes made to the patient’s data via 
a data query  will be approved by  the Investigator prior to final database lock.
After all data have been reviewed and all issues have been resolved, the database will be locked.
All data collected in the context of this study  will be stored and evaluated per regulatory  
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated in such a way  as to guarantee patient confidentiality  in accordan ce with the 
legal stipulations apply ing to confidentiality  of data. Study  records (eg, copies of eCRFs, 
laboratory  reports, and regulatory  documents) will be retained at the study  center, along 
with adequate source documentation, according to FDA and ICH requirements. All study  
records must be available for inspection b y the Sponsor, its authorized representatives, 
the FDA, or other health authorities.
Data for the  C-SSRS, BPRS+, CADSS, and  will be captured 
using an electronic source tablet- based system.   
 
 
Source documents will be used at the 
study centers and may  include a patient’s medical record, hospital charts, clinic charts, 
the Investigator’s patient study  files, as well as the results of diagnostic tests such as 
laboratory  tests, ECGs, etc. A centralized clinical laboratory  will be used for the anal ysis 
of all blood samples. Additional information on the collection and handling of samples is 
detailed in the Lab Procedure Manual. 
RAP-MD-06 Protocol Page 59 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.7 STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
9.7.1 Analysis Populations
Threepopulations will be considered in the statistical anal ysis of the study , as specified 
in the following subsections.
9.7.1.1 Screened Population
The Screened Population will consist of all patients who signed the RAP-MD-06 ICF if 
they participated in Study RAP-MD-04, and all patients who underwent the Screening 
Visit, received a PID number, and signed the ICF if they  didn’t participate in Study 
RAP-MD-04.
9.7.1.2 Safety Population
The Safet y Population will consist of all patients in the Screened Population who took at 
least 1 dose of rapastinel during the OLTPof the study .
9.7.1.3 Intent-to-Treat Population
The Intent -to-Treat (ITT) Population will consist of all patients in the Safety  Population 
who had at least 1 postbaseline assessment of the MADRS total score during the OL TP
of the study .
9.7.2 Patient Disposition
The number and percentage of patients in the 3 analy sis populations will be summ arized 
overall by study center. 
For de novoenrolled patients, screen failures (ie, patients who were screened but not 
included in the Safet y Population) and the associated reasons for failure to enroll will be 
tabulated overall for the Screened Population.
The number and percentage of patients who complete the OLTP , who prematurel y 
discontinue from the OLTP, and who complete the safet y follow-up period will be 
summarized overall and by  reasons for premature discontinuation for the Safet y 
Population. 
RAP-MD-06 Protocol Page 60 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.7.3 Demographics and Other Baseline Charac teristics
Demographic parameters (eg, age, race, ethnicit y, sex, weight, height, body mass index) 
and other baseline characteristics will be summarized overall for the Safet y Population 
and the ITT Population. 
9.7.4 Extent of Exposure and Treatment Compliance
9.7.4.1 Extent of Exposure
Exposure to rapastinel for the Safet y Population during the OLTPwill be summarized for 
treatment duration, calculated as the number of day s from the date of the first dose of 
open-label rapastinel taken to the date of the last dose taken during the OLTP , inclusive. 
Descriptive statistics (n umber of patients , mean, SD , minimum, median, and maximum) 
will be presented.
Prior medication will be defined as an y medication started before the date of first dose of 
IPin the first lead- in study for rollover patients or any medication started before the date 
of the first dose of open -label IP in this study  for de novopatients. Concomitant 
medication during the OLTP will be defined as any  medication taken on or after the date 
of the first dose of open -label IPduring the OLTP . 
The use of prior medication will be summarized by the number and percentage of patients 
receiving each medication within each therapeutic class for the Safet y Population. The 
use of concomitant medications during the OLTPwill be summarized by  the number a nd 
percentage of patients receiving each medication within each therapeutic class for the Safety Population. Multiple use of the same medication by  a patient will only  be counted 
once.
The number and percentage of patients taking each qualify ing ADT in the OLTPwill be 
summarized for the Safety Population. Mean dail y dose and duration of treatment with 
each qualify ing ADT will be summarized using descriptive statistics (number of patients, 
mean, SD, median, minimum, and maximum) for the Safet y Population.
9.7.4.2 Measurement of Treatment Compliance
Dosing compliance for a specified period is defined as the total number of IV doses 
actually taken by a patient during that period divided by  the number of IV doses that were 
expected to be taken duringthe same period multiplied by  100. Descriptive statistics for 
IP compliance will be presented for each week, as well as for the whole OLTP for the 
Safety Population. 
RAP-MD-06 Protocol Page 61 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Dosing compliance for the background ADT during a specified period is defined as the 
dosesactually taken bya patient during that period divided by  the dose expected to be 
taken during the same period multiplied by  100. Descriptive statistics for ADT 
compliance during the OLTPwill be presented for each ADT for the Safety  Population.
 
 
 
 
 
 
9.7.6 Safety Analyses
The safety analysis will be performed using the Safety  Population, defi ned as all patients 
who receive at least 1 dose of IP during the OLTP . 
The safety parameters will include AEs ;clinical laboratory , vital sign s, and ECG 
parameters; and the BPRS+, CADSS , .
For each safety parameter, the last assessment made before the first dose of open -label IP
will be used as the baseline for de novo patients, and the baseline of the first lead- in study 
will be used as the baseline for rollover patients for all anal yses of that safety  parameter .
Continuous variables will be summarized by number of patients and mean, SD, median, minimum, and maximum values. Categorical variables will be summarized by  number 
and percentage of patients. 
RAP-MD-06 Protocol Page 62 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.7.6.1 Adverse Events
AEs will be coded b y system organ class (SOC) and preferred term using the Medical 
Dictionary for Regulatory Activities .
For rollover patients, an AE (classified b y preferred term) that occur s during the OLTP
will be considered a treatment -emergent adverse event ( TEAE)if it was not present 
before the first dose of IP in the first lead -in studyor was present before the first dose of 
IPin the first lead- in studyand increased in severity  during the OLTP. If more than 1 AE 
is reported before the first dose of I Pin the first lead -in studyand coded to the same 
preferred term, the AE with the greatest severity will be used as the benchmark for 
comparison with the AEs occurring during the OLTPthat were also coded to that 
preferred term.
For de novopatients, a n AE (classified b y preferred term) that occurs during the OLTP 
will be considered a TEAE if it was not present beforethe first dose of open- label IPor 
was present before the date of the first dose of open -label IPand increased in severit y 
after the first dose of open-labelIP. If more than 1 AE is reported before the first dose of 
open-label IPand is coded to the same preferred term, the AE with the greatest severit y 
will be used for comparison with the AEs occurring during the OLTPthat were also 
coded to that preferred term. An AE that occurs more than 30 day s after the date of the last dose of IP will not be
considered a TEAE.A TEAE occurring during the OLTP will be con sidered a newl y emergent AE (NEAE) if 
the AE was not present before the first dose of open -label IP or was present before the 
first dose of open -label IP but increased in severity during the OLTP. The number and 
percentage of patients reporting NEAEs durin g the OLTP will be summarized by SOC
and preferred term.The number and percentage of patients reporting TEAEs will be tabulated by SOC and 
preferred term and further categorized by  severity and causal relationship to the I P. If 
more than 1 AE is coded to the same preferred term for the same patient, the patient will 
be counted onl y once for that preferred term using the greatest severit y and strictest 
causality for the summarization by  severity and causal relationship.
The distribution of TEAEs by severit yand relationship to the I P will be summarized. 
An AE that occurs more than 30 day s after the date of the last dose of IPwill not be 
summarized.
The incidence of common ( ≥ 2% of patients) TEAEs and AEs leading to premature 
discontinuation of I P will be s ummarized by  preferred term and will be sorted by  
decreasing frequency .  
RAP-MD-06 Protocol Page 63 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
An SAE that occurred between the date of the first dose of the open -label IPand 30 day s 
after the date of the last dose of IP, inclusive, will be considered an on -therapy SAE. 
The number and percentage of patients who ha veon-therapy SAEs will b e summarized 
by preferred term . In addition, the incidence of on -therapy SAEs that led to death will be 
summarized separatel y by preferred term.
The incidence of AEs leading to premature disc ontinuation of IPduring the OL TPwill be 
summarized by  preferred term and will be sorted by  decreasing frequency . 
Listings will be presented for all patients with SAEs, patients with AEs leading to 
discontinuation, and patients who die (if an y). All patients with SAEs, including SAEs 
reported during the screening period and the s afety follow-up period, and patients 
discontinuing because of AEs occurring before the start of I P will be included in these 
listings.
9.7.6.2 Clinical Laboratory Parameters
Descriptive statistics for clinical laboratory  values (in SI  units) and changes from baseline 
values at each assessment timepoint will be presented for each clinical laboratory  
parameter .
In addition, descriptive statistics for values and changes from the base line values in 
conventional units at each assessment timepoint will be presented for selected clinical 
laboratory  parameters listed in the Statistical Analysis Plan (SAP).
The number and percentage of patients who have potentially  clinically significant (P CS) 
postbaseline clinical laboratory  values will be tabulated . The criteria for PCS laboratory  
values will be detailed in the SAP. The percentages will be calculated relative to the number of patients with available non -PCS baseline values and at least 1 postbaseline 
assessment for the OLTP . The numerator will be the total number of patients with 
available non- PCS baseline values and at least 1 PCS postbaseline value. A supportive 
tabular display of patients with PCS postbaseline value swill be provided, including the 
PID number, baseline, and all postbaseline (including non- PCS) values. In addition, a 
tabular display  showing all AEs that occurred in patients who had PCS postbaseline 
clinical laboratory  values will be provided.
Shift tables from baseline to end of stud y for clinical laboratory  parameters will be 
presented for the following categories: low, normal, and high, which are provided by the
laboratory vendor.
Patients who meet the potential Hy ’s Law criteria from the first dose of IPto within 
30days after the last dose of IPwill be summarized. Supportive tabular display s will also 
be provided. 
RAP-MD-06 Protocol Page 64 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.7.6.3 Vital Signs
Descriptive statistics for vital signs ( eg, pulse rate, sy stolic and diastolic BP, body  
weight, oral or tympanic temperature, and body weight)and changes from baseline 
values at each visit and at the end of study  will be presented.
Vital sign values will be PCSif they meet both the observed -value criteria and the change 
from baseline value criteria. T he criteria for PCS vital sign values will be detailed in the 
SAP. The percentages will be calculated relative to the number of patients with available 
non-PCS baseline values and at least 1 postbaseline assessment for the OLTP or the 
safety follow-up period. The numerator will be the total number of patients with available 
baseline values and at least 1 PCS postbaseline value. A supportive listing of patients 
with postbaseline PCS values will be provided, including the PID number, baseline 
values, and postbaseline values. A listing of all AEs occur ring in patients who ha vePCS 
vital sign values will also be provided.
9.7.6.4 Electrocardiogram
Descriptive statistics for ECG parameters (ie, heart rate, PR interval, QRS interval, RR interval, QT interval, QTcB interval, and QTcF interval) and changes from base line 
values at each assessment timepoint will be presented.
The number and percentage of patients with PCS postbaseline ECG values will be 
tabulated for the OLTP. The criteria for PCS ECG values will be detailed in the SAP. The 
percentages will be calculated relative to the number of patients with available non- PCS 
baseline values and at least 1 postbaseline assessment for the OLTP . The numerator isthe 
total number of patients with available non- PCS baseline values and at least 1 PCS 
postbaseline value. A supportive tabular display of patients with PCS postbaseline values 
will be provided, including the PID number, baseline values, all postbaseline (including 
non-PCS) values, and change from baseline. In addition, a tabular display  showing all 
AEs that occurredin patients who had postbaseline PCS ECG values will be provided.
A shift table from baseline to the end ofstudy in the Investigator’s overall interpretation 
of the ECG will be presented for the following categories:  normal; abnormal, not clinically significant; and abnormal, clinicall y significant. A tabular display  showing 
patients with postbaseline clinically  significant ECG abnormalities according to the 
Investigator’s overall interpretation will be provided.
The number and percentage of patients with change from baseline QTc> 30 msec but not 
exceeding 60 msec and of patients with an increase > 60 msec wil l be tabulated. A 
supportive listing that includes the PID number, all QTc values (including change from 
baselinevalues), and all AEs will be provided for all patients who have postbaseline QTc 
changes > 30 msec. 
RAP-MD-06 Protocol Page 65 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
9.7.6.5 Other Safety Parameters
Other safety  parameters comprise the BPRS+, CADSS,
Descriptive statistics of actual values and change from baseline for BPRS+ total score 
will be presented at each assessment timepoint during the OLTP.
Descriptive statistics of actual values and change from baseline for CADSS total score 
will be presented at each assessment timepoint during the OLTP. CADSS total score is 
defined as the sum of scores for 23 subjective items.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RAP-MD-06 Protocol Page 66 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

9.7.8 Interim Analysis
No interim anal ysis is planned for this study .
9.7.9 Determinati on of Sample Size
Approximately  500 patients are expected to enter the OLTP. The study  will be terminated 
when100 patients have completed the 52-week OLTP.
9.7.10 Computer Methods
Statistical analy ses will be performed using  
.
9.8 CHANGES IN THE CONDU CT OF THE STUDY OR P LANNED 
ANALYSES
Any amendment to this protocol will be provided to the Investigator in writing by  the 
Sponsor. No protocol amendment may  be implemented (with the exceptions noted below)
before it has been approved by  the IRB and the signature page, signed by  the
Investigator , has been received by  the Sponsor . If the protocol is amended to eliminate or 
reduce the risk to patients, the amendment may  be implemented before IRB review and 
approval. However, the IRB must be informed in writing of such an amendment ,and 
approval must be obtained within reasonable time limits . 
9.9 PROTOCOL DEVIATIONS
A protocol deviation is any change, divergence, or departure from the study  design or 
procedures tha t is under the Investigator ’sresponsibility  and oversight (as defined by  
regulations) without prior written IRB approval or favorable opinion of an appropriate 
amendment and that does not have a major impact on the patient’s rights, safety , or 
well-being,or on the integrity and authenticity of the study data. Deviations may include, 
but are not limited to, departure from inclusion/exclusion criteria, dosing, duration of treatment, failure to perform the required assessments at specified timepoints, schedu ling 
of visits not in accordance with specifications, or patientsafety.Deviating from the 
protocol is permitted only if absolutel y necessary for the safet y or clinical management of 
the patient s and must immediately  be reported to the Sponsor .
Protocol deviations must be reported to the Sponsor either ver bally or electronically 
within 5 working day s from the day of discovery . 
RAP-MD-06 Protocol Page 67 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

An important protocol deviation is a form of protocol deviation that has a major impact 
on the patient ’s rights, safety , or well-being, or on the integrit y and authenticity  of the 
study data.Important protocol deviations must be reported to the Sponsor within 
24hours,if possible. The I RB must be notified within the time period dictated by  the IRB
associated with this study .  
RAP-MD-06 Protocol Page 68 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
10.0 STUDY SPONSORSHIP
This study  is sponsored by Naurex, Inc, an affiliate of Allergan, plc .
10.1 STUDY TERMINATION
The Sponsor reserves the right to terminate the study  in its entiret y or at a specific study  
centerbefore study completion. 
10.2 REPORTING AND PUBLICAT ION
All data generated in this study  arethe propert y of the Sponsor . An integrated clinical and
statistical report will be prepared at the completion of the study .
Publication of the results by  the Investigatorwill be subject to mutual agreement between 
the Investigator and the Sponsor and will follow the Sponsor’s Standard Operating 
Procedure on publications. 
RAP-MD-06 Protocol Page 69 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
11.0 INVESTIGATOR OBLIGAT IONS
11.1 DOCUMENTATION
The Investigator must provide the following to the Sponsor beforethe start of the study :
A completed and signed Form FDA 1572. If,during the course of the study ,any 
changes are made that are not reflected on Form FDA 1572, a new Form FDA 1572 
must be completed and returned to the Sponsor for submission to the FDA.
A fully executed contract
The curriculavitae for the Investigator and all subinvestigator s listed on Form FDA 
1572, including a cop y of each ph ysician’s license
A copy of the origi nal IRB approval for conducting the study . If the study is ongoing, 
renewals must be submit ted at yearly intervals . All subsequent modifications must be 
submitted and approved by  the IRB, as stated in Section5.1.
A copy of the IRB -approved ICF
A copy of the H IPAA authorization form, or other local privacy applicable forms
A list of the IRB members or the DHHS general assurance number
A copy of the laboratory certifications and reference ranges
The Investigator’s Statement page in this protocol, signed and dated b y the 
Investigator
Financial disclosure agreement completed and signed by  the Investigator and all 
subinvestigator s listed on Form FDA 1572. The Investigator and all subinvestigator s 
will provide an updated financial disclosure agreement to the Sponsor 1 y ear after the 
completion of the study .
11.2 PERFORMANCE
The Investigator must demonstrate reasonable efforts to obtain q ualified patient s for the 
study. 
RAP-MD-06 Protocol Page 70 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
11.3 USE OF INVESTIGATIONAL MATERIALS
The Investigator will acknowledge that the IPsupplies are investigational and as such 
must be used strictly  in accordance with the protocol and only under the supervision of 
the Investigatoror Subinvestigator s listed on Form FDA 1572. The IPmust be stored in a 
securedplaceand must be locked . At study  initiation ,a representative from the Sponsor
will inventory  the IPat the study center. The Investigator must maintain adequate records 
documenting the receipt and disposition of all study  supplies. The Sponsor will supply  
forms on which to record the date the IPwasreceived and a dispensing record in which 
to record each patient’s use . All unused IPmust be returned to the Sponsor.
11.4 CASE REPORT FORMS
All patientdata relating to the study  will be recorded on eCRF sto be provided by  the 
Sponsorthrough the EDC sy stem. The Investigator is responsible for verify ing that all 
data entries in the eCRFs are accurate and correct by  electronically  signing the completed 
eCRF casebook submitted to the Sponsor . The Investigator must maintain and retain 
accurate documentation that supports the information entered into the EDC sy stem for 
source document verification and possible regulatory  inspection.
11.5 RETENTION AND REVIEW O F RECORDS
Records and documents pertaining to the conduct of this study , including eCRFs, source 
documents, consent forms, regulatory  documents, clinical laboratory  results, calibration 
logs,or reports (including, but not limited to, a ll local and central laboratory results and 
ECG reports), and medication inventory  records in all formats (including, but not limited 
to, written, electronic, magnetic, and optical records, and scans, x -rays, and ECGs) must 
be retained b y the Investigator for a period of at least 15 y ears after study  completion 
unless local regulations or institutional policies require a longer retention period or 
otherwise notified in writing b y the Sponsor. 
No study records shall be destroy ed without notifying the Sponsor and providing the 
Sponsor the opportunity  to arrange long -term storage for such study  records or 
authorizing in writing the destruction of records after the required retention period.
The Investigator must permit access to any  documentation relating to the study  upon 
request of the Sponsor or applicable regulatory  authorities. If the Investigator for the 
study retires, relocates, or for other reasons withdraws from the responsibility of keeping 
the study records, custody  must be transferred to a suitable alternate custodian employ ee 
of the institution or to a suitably  qualified and responsible third party . The Sponsor must 
be notified in writing of the name and address of the new custodian in advance of the 
transfer. 
RAP-MD-06 Protocol Page 71 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
11.6 PATIENT CONFIDENTIALITY
All patientrecords will only  be identified by initials and PIDnumber. Patients’ names are 
not to be transmitted to the Sponsor . The Investigator will keep a m aster patient list on 
which the PI Dnumber and the full name, address, and telephone number of each patient
are listed. 
RAP-MD-06 Protocol Page 72 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
12.0 INVESTIGATOR’S STATE MENT
I agree to conduct the study in accordance with this protocol(RAP-MD-06, dated 
07 Jun 2016) and with all applicable government regulations and good clinical 
practice guidance.
_______________________________________ _____/_____/______
Investigator’s Signature Date
_______________________________________
Investigator’s Name 
RAP-MD-06 Protocol Page 73 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
13.0 APPENDICES
APPENDIX I. ELEMENTS OF INFORMED CONSENT
Procedures will comply  with 21 CFR, Parts 50 and 312 . Signed informed consent will be 
obtained for each patient participating in a clinical research study. This consent must 
include the following items:
A statement that the study involves research and an explanation of the purposes of the 
research; a descript ion of the procedures to be followed and the identification of any  
procedures that are experimental; and the expected duration of the patient’s 
participation
A description of an y reasonably  foreseeable risks or discomforts to the patient
A description of a ny benefits to the patientor to others that may  reasonably  be 
expected from the research. If the patientis to be paid for participating in the study , 
the consent form must state the amount that he/she will receive and the schedule of 
payment (to ensure n either coercion nor undue influence) .
A disclosure of appropriate alternative procedures or courses of treatment, if an y, that 
might be advantageous to the patient
A statement describing the extent, if any , to which confidentiality  of records 
identifying the patientwill be maintained and noting the possibility  that the FDA, the 
Sponsor,the IRB,or an authorized contract research organization may  inspect the 
records
For research involving more than minimal risk, an explanation of whether any  
medical treatment is available if injury  occurs and, if so, what it consists of or where 
further information may be obtained
An explanation of whom to contact, including the relevant telephone number, for 
answers to pertinent questions about the research and the researc h patient’s rights and 
whom to contact in the event of a research -related injury  to the patient . (Note: In 
some cases ,it may be necessary  to identify  a person other than the Investigator as the 
contact. The guidance of the I RB maybe required.)
A statement that participation is voluntary , that refusal to participate will involve no 
penalty or loss of benefits to which the patient is otherwise entitled, and that the 
patientmay discontinue participation at any  time without penalty  or loss of benef its to 
which the patient is otherwise entitled 
RAP-MD-06 Protocol Page 74 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
A statement that the particular treatment or procedures may  involve risks to the 
patient(or to the embry o or fetus if the patient is, or may  become, pregnant) that are 
at present unforeseeable
The expected ci rcumstances forwhich the patient ’s participation may  be terminated 
by the Investigatorwithout regard to the patient’s consent
Any additional costs to the patient that may result from participation in the research
The consequences of a patient’s decision to withdraw from the research and 
procedures for an orderly termination of the patient’s participation
A statement that significant new findings developed during the course of the research 
that may relate to the patient’s willingness to continue participat ion will be provided 
to the patient
The approximate number of patients involved in the study
A statement of permission, providing consent for the patient to participate (eg,“I 
agree to participate . ..”)
A place for the patient’s signature and date of signingof the ICF
A statement indicating that information about this study  has been, or will be, entered 
into a databank that is publicly  accessible at www.ClinicalTrials.gov.
A copy of the signed consent form must be given to the patient. 
RAP-MD-06 Protocol Page 75 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
APPENDIX II. CONTACT INFORMATION 
Contact information for the Sponsor personnel is maintained in the Study  Reference 
Manual. 
RAP-MD-06 Protocol Page 76 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
 
RAP-MD-06 Protocol Page 77 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 78 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 79 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 80 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 81 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
RAP-MD-06 Protocol Page 82 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 83 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 84 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 85 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 86 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 87 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 88 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 89 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 90 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 91 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
  
RAP-MD-06 Protocol Page 92 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
RAP-MD-06 Protocol Page 93 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 94 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 95 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 96 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 97 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 98 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 99 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 100 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 101 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 102 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 103 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 104 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 105 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 106 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
  
RAP-MD-06 Protocol Page 107 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
RAP-MD-06 Protocol Page 109 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
RAP-MD-06 Protocol Page 110 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

 
   
RAP-MD-06 Protocol Page 111 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
07 Jun 2016Naurex, an affiliate of Allergan, plc.

  
RAP-MD-06 Protocol Page 113 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.

14.0 LITERATURE CITED
Abilify [package insert]. Toky o, Japan; Otsuka Pharmaceutical Co., L td. December 2014.
American Ps ychiatric Association (2013). Diagnostic and statistical manual of mental 
disorders: DSM -5. Washington, DC: American Psy chiatric Association.
Ashton AK, Jamerson BD, Weinstein W, Wagoner C. Antidepressant- related adverse 
effects impacting treatment compliance: Results of a patient sur vey. Curr Ther Res Clin 
Exp. 2005Mar;66(2):96- 106.doi:10.1016/j.curtheres.2005.04.006.
Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey -Lisle PK, et al . 
The efficacy  and safet y of aripiprazole as adjunctive therap y in major depressive 
disorder: a multicenter, randomized, double -blind, placebo -controlled study. J Clin 
Psychiatry. 2007Jun;68(6):843-53.
Boland RJ, Keller MB. Treatment of depression. In: Schatzberg AF, Nemeroff CB, 
editors. Essentials of clinical psy chopharmacology. 2nd ed. Arlin gton, VA: American 
Psychiatric Publishing, Inc; 2006. p 465 -78.
Bremner JD, Kry stal JH, Putnam FW, Southwick SM, Marmar C, Charney  DS, et al. 
Measurement of dissociative states with the Clinician -Administered Dissociative States 
Scale (CADSS). J Trauma Str ess. 1998Jan;11(1):125–36.
Fava M, Davidson KG. Definition and epidemiology  of treatment -resistant depression. 
Psychiatr Clin North Am . 1996Jun;19(2):179- 200.
FDA Guidance for Industry : Drug Induced L iver Injury -Pre-Marketing Clinical 
Evaluation, July  2009.
Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, L owe SW, Berglund PA, et al. 
The economic burden of depression in the United States: how did it change between 1990 
and 2000? J Clin Psy chiatry. 2003Dec;64(12):1465-75.
Gualtieri CT, Johnson LG. Reliability  and validity  of a computerized neurocognitive test 
battery, CNS Vital Signs. Arch Clin Neurops ychol. 2006 Oct;21(7):623 -43. 
Guy W. ECDEU assessment manual for ps ychopharmacology —revised. DHEW 
publication no. ADM 76 -338. Rockville, MD: US Department of Health, Education, and 
Welfare; Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration; National I nstitute of Mental Health; Psy chopharmacology  Research 
Branch; Division of Extramural Research Programs; 1976. p. 218-22. 
RAP-MD-06 Protocol Page 114 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Herdman M, Gudex C, Lloy d A, Janssen M, Kind P, Parkin D, et al. Development and 
preliminary  testing of the new five- level version of EQ -5D (EQ-5D-5L). Qual Life Res.
2011 Dec; 20 (10):1727 -36.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime 
and 12-month prevalence of DSM- III-R psychiatric disorders in the United States: results 
from the National Comorbidity  Study.  Arch Gen Psy chiatry. 1994Jan;51(1):8-19.
Kessler RC, Chiu WJ, Demler O, Merikangas KR, Walters EE.   Prevalence, severit y, and 
comorbidity  of 12-month DSM- IV disorders in the National Comorbidity  Survey. Arch 
Gen Psychiatry. 2005Jun;62(6): 617-27.
Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, 
et al.  The e fficacy and safet y of aripiprazole as adjunctive therap y in major depressive 
disorder: a second multicenter, randomized, double- blind, placebo -controlled study . 
JClin Psychopharmacol . 2008Apr;28(2):156-65.
Masand PS. Tolerability  and adherence issues in antidepressant therapy . Clin Ther . 2003
Aug;25(8):2289-304. Review.
McIntyre RS and O’Donovan C.  The human cost of not achieving full remission in 
depression.  Can J Psy chiatry.2004Mar;49(3 Suppl 1):10S -16S.
Montgomery  SA, Åsberg M. A new depression scale designed to be sensitive to change. 
Br J Psychiatry . 1979Apr;134:382-9.
Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US 
health, 1990 -2010: burden of diseases, injuries, and risk factors. JA MA. 2013
Aug14;310(6):591-608. 
Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, et al. 
Ketamine and other NMDA antagonists: earl y clinical trials and possible mechanisms in 
depression. Am J Psy chiatry.2015Oct;172(10):950-66.
Overall JE and Gorham DR. The brief ps ychiatric rating scale. Psychological Reports.
1962;10:799-812.
Rapastinel: I nvestigator’s Brochure. Edition 7. Evanston, IL : Naurex, I nc; 01Jul2014.
Rexulti [package insert].  Toky o, Japan; Otsuka Pharmaceutical Co., Ltd.  August 2015.
Rosenzweig -Lipson S, Bey er CG, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, et al.  
Differentiating antidepressants of the future: efficacy  and safet y.  Pharmacol Ther . 2007
Jan;113(1):134-53. 
RAP-MD-06 Protocol Page 115 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 
Acute and longer -term outcomes in depressed outpatients requiring one or several 
treatment steps: a STAR*D report.  Am J Psy chiatry. 2006Nov;163(11):1905-17.
Sachdev P.  The epidemiology  of drug-induced akathisia :partII. Chronic, tardive, and 
withdrawal akathisias.  Schizophren Bull .1995;21(3):451 -61.
Seroquel [package insert].  Wilmington, DE; A straZeneca Pharmaceuticals LP. October 
2013.
Smith DW, Jones, KL . (1982) Recognizable Patterns of Human Malformation. (3rded.) 
Philadelphia: Saunders.Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication 
augmentation after the failure of SSRI s for depression.  N Engl J Med . 2006Mar 
23;354(12):1243 -52.
Videbech P and Ravnkilde B.  Hippocampal vo lume and depression: a meta -analysis of 
MRI studies. Am J Psy chiatry. 2004Nov;161(11):1957-66.
World Health Organization.  Mental health: new understanding, new hope. World Health 
Report. 2001. 
RAP-MD-06 Protocol Page 116 of 116
07 Jun 2016Naurex, an affiliate of Allergan, plc.